uniQure N.V.
QURE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.9B
Close$
$-8.56
120.6% downside
Current Fair Value
120.6% downsideOvervalued by 120.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.90 Billion |
|---|---|
| Enterprise Value | $2.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.46 |
| Beta | 0.9 |
| Outstanding Shares | 62,742,847 |
Return
| Return on Equity | -139.86% |
|---|---|
| Return on Assets | -26.82% |
| Return on Invested Capital | -32.82% |
Valuation & Multiples
| P/E Ratio | -12.15 |
|---|---|
| PEG | -53.54 |
| Price to Sales | - |
| Price to Book Ratio | 20.76 |
| Enterprise Value to Revenue | 156.01 |
| Enterprise Value to EBIT | -11.95 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$5.24 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.83
Average shareholder expectationRevenue Estimate
$5.45 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 14.82% |
|---|---|
| Total Calls | 35▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.06%▼ 102.58% |
|---|---|
| Total Invested | $30.51M▼ 96.85% |
| Investors Holding | 9▼ 249.00% |
ESG Score
No data
About uniQure N.V.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...